**5. Conclusion**

Given the diverse molecular and genetic alterations occurring in both CLL and ALL, it is unlikely that a single and unique therapeutic approach will be effective across all patients. Great progress has been made thus far in the identification of oncogenic drivers and therapeutic targets. However, although treatment regimens have advanced significantly, they continue to present many challenges for the majority of patients, including toxicity. Future studies focused on the identification of biomarkers should result in more effective treatments exhibiting antileukemic activity with reduced toxicity. Furthermore, highly targeted therapy can be expected to lead to improvements in remission and survival as part of individualized treatment strategies.

**87**

**Author details**

Martina Maďarová1

1 DB Biotech Inc., Košice, Slovakia

2 BLES Biochemicals Inc., London, ON, Canada

provided the original work is properly cited.

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

and Tomas Dobransky1

\*

, Dominik Dobransky2

\*Address all correspondence to: tdobransky@dbbiotech.com

*New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia*

*DOI: http://dx.doi.org/10.5772/intechopen.85449*
